Cargando…
Perampanel as First Add-On Therapy in Patients with Focal-Onset Seizures in the FAME Trial: Post hoc Analyses of Efficacy and Safety Related to Maintenance Dose and Background Antiepileptic Drug Therapy
BACKGROUND AND PURPOSE: FAME (Fycompa(®) as first Add-on to Monotherapy in patients with Epilepsy; NCT02726074), a previously reported single-arm, phase IV study, showed that perampanel improved seizure control as first add-on to failed anti-seizure medication (ASM) monotherapy in 85 South Korean pa...
Autores principales: | Kim, Ji Hyun, Kim, Dong Wook, Lee, Sang Kun, Seo, Dae-Won, Lee, Ji Woong, Kim, Min Young, Lee, Sang Ahm |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Epilepsy Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289376/ https://www.ncbi.nlm.nih.gov/pubmed/35910326 http://dx.doi.org/10.14581/jer.22003 |
Ejemplares similares
-
Perampanel as First Adjunctive Treatment in Patients with Focal-Onset Seizures in the FAME Study: Post hoc Analyses of Dose-Related Efficacy, Safety and Clinical Factors Associated with Response
por: Kim, Dong Wook, et al.
Publicado: (2022) -
First add‐on perampanel for focal‐onset seizures: An open‐label, prospective study
por: Kim, Ji Hyun, et al.
Publicado: (2019) -
Successful Treatment of Drug-Resistant Seizures Secondary to Ring 20 Mosaicism with Perampanel as an Add-On Antiepileptic Drug
por: Ling, Janet, et al.
Publicado: (2022) -
Efficacy and safety of perampanel as early add-on therapy in Chinese patients with focal-onset seizures: a multicenter, open-label, single-arm study
por: Gao, Lehong, et al.
Publicado: (2023) -
Seizure remission and improvement of neurological function in sialidosis with perampanel therapy
por: Hu, Su-Ching, et al.
Publicado: (2018)